Whereas the Process Pressure’s work stays ongoing, these hearings proceed to provide sturdy indications of the general course of the hassle, and the doubtless important adjustments for antitrust enforcement going ahead.
Is FTC’s Grievance in Meta/Inside an Ominous Signal for Large Pharma?
On July 27, 2022, the FTC filed a criticism within the U.S. District Court docket for the Northern District of California looking for to enjoin Meta Platforms, Inc.’s proposed acquisition of Inside Limitless, Inc.2 As described in additional element in our Antitrust + Competitors Expertise Quarterly Replace Q2 2022, the FTC’s criticism alleges that the acquisition constitutes “yet one more step alongside [Meta’s] path towards dominance” of the digital actuality house, and poses a “affordable probability of considerably lessening competitors out there for VR devoted health apps.” (Grievance at 8)
Comments
0 comments